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Background: The clinical features of atherosclerotic lesions in ketosis-onset diabetes are largely absent. We aimed
to compare the characteristics of lower limb atherosclerotic lesions among type 1, ketosis-onset and non-ketotic
type 2 diabetes.
Methods: A cross-sectional study was performed in newly diagnosed Chinese patients with diabetes, including 53
type 1 diabetics with positive islet-associated autoantibodies, 208 ketosis-onset diabetics without islet-associated
autoantibodies, and 215 non-ketotic type 2 diabetics. Sixty-two subjects without diabetes were used as control.
Femoral intima-media thickness (FIMT), lower limb atherosclerotic plaque and stenosis were evaluated and
compared among the four groups based on ultrasonography. The risk factors associated with lower limb
atherosclerotic plaque were evaluated via binary logistic regression in patients with diabetes.
Results: After adjusting for age and sex, the prevalence of lower limb plaque in the patients with ketosis-onset
diabetes (47.6%) was significantly higher than in the control subjects (25.8%, p = 0.013), and showed a higher trend
compared with the patients with type 1 diabetes (39.6%, p = 0.072), but no difference was observed in comparison
to the patients with non-ketotic type 2 diabetes (62.3%, p = 0.859). The mean FIMT in the ketosis-onset diabetics
(0.73 ± 0.17 mm) was markedly greater than that in the control subjects (0.69 ± 0.13 mm, p = 0.045) after controlling
for age and sex, but no significant differences were found between the ketosis-onset diabetics and the type 1
diabetics (0.71 ± 0.16 mm, p = 0.373), and the non-ketotic type 2 diabetics (0.80 ± 0.22 mm, p = 0.280), respectively.
Age and FIMT were independent risk factors for the presence of lower limb plaque in both the ketosis-onset and
non-ketotic type 2 diabetic patients, while sex and age in the type 1 diabetic patients.
Conclusions: The prevalence and risk of lower limb atherosclerotic plaque in the ketosis-onset diabetes were
remarkably higher than in the control subjects without diabetes. The features and risk factors of lower limb
atherosclerotic lesions in the ketosis-onset diabetes resembled those in the non-ketotic type 2 diabetes, but
different from those in the type 1 diabetes. Our findings provide further evidences to support the classification of
ketosis-onset diabetes as a subtype of type 2 diabetes rather than idiopathic type 1 diabetes.
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Ketosis-prone diabetes or atypical diabetes, manifested by
remarkable insulin deficiency at diagnosis accompanied by
unprovoked ketoacidosis without identifiable precipitating
causes, and absence of islet-related autoantibodies, has
been proposed as idiopathic or type 1B diabetes by the
World Health Organization and the American Diabetes
Association [1,2]. However, recent several studies, which
suggested that patients with ketosis-prone diabetes pos-
sessed higher age of onset and BMI, ethnic-specific gene
variants, and even a very variable response to diet and oral
agents [3-6], have lent support to this idea that ketosis-
prone diabetes is a subgroup of type 2 diabetes.
The comparisons of metabolic and immunologic char-
acteristics among type 1, ketosis-prone and type 2 diabetes
have been well established [7-9]. However, the prevalence
and clinical characteristics of atherosclerosis and its com-
plications are largely absent in ketosis-prone diabetes. In a
previous study, we found that the prevalence and risk of
carotid atherosclerosis in ketosis-onset diabetes were re-
markably higher than those in subjects without diabetes,
but resembled those in type 2 diabetes [10]. Furthermore,
the features of carotid atherosclerotic lesions in ketosis-
onset diabetes were also similar to those in type 2 diabetes
[10]. However, because of a lack of type 1 diabetic group
in our previous study, the differences of carotid athero-
sclerotic lesions could not be compared between type 1
and ketosis-onset diabetes.
In the current study, type 1 diabetes consisted of
childhood-onset type 1 diabetes (≥17 years old) and la-
tent autoimmune diabetes in adults (LADA), and the
latter were frequently misdiagnosed as type 2 diabetes.
In China, the former was infrequent (0.51 per 100,000)
[11] while the latter was prevalent (5.9% for Chinese
newly diagnosed type 2 diabetes) [12], and autoantibody
(usually GAD antibody) is one of the most important
factors to distinguish type 1 diabetes from type 2 diabetes
[13]. The 53.4% of frequency of positive tests for anti-
GAD was higher than the 25.8% frequency of positive IA-
2 autoantibody in Chinese patients with type 1 diabetes
[14]. In addition, the frequency of positive GAD or IA-2
antibodies was significantly higher in patients with type 1
diabetes than in those with type 2 diabetes [15-17].
It is generally accepted that accelerated atherosclerosis
and its complications are typical features of type 2 dia-
betes [18,19]. For example, Scholte et al. [19] observed
that the prevalence of coronary atherosclerosis reached
to 80% even in asymptomatic type 2 diabetic patients.
On the contrary, as the early-stage lesions of type 1 dia-
betes, diabetic microvascular complications, especially dia-
betic nephropathy, are main reasons for the morbidity and
mortality in patients with type 1 diabetes reported by
previous studies [20,21]. However, several recent studies
found a higher prevalence of microvascular brain lesionsin type 2 diabetics relative to non-diabetics and there was
also a significant association between microvascular brain
lesions and diabetes even after correction for other risk
factors in type 2 diabetic patients [22,23]. Therefore, it is
of great significance to discuss diagnostic classification of
ketosis-prone diabetes from macroangiopathy angle.
Thus, one of the aims of the present study was to in-
vestigate the prevalence and features of lower limb ath-
erosclerotic lesions in newly diagnosed Chinese patients
with ketosis-onset diabetes. Secondly, we aimed to com-
pare the characteristics of lower limb atherosclerotic
lesions among control subjects, type 1 diabetes, ketosis-
onset diabetes and non-ketotic type 2 diabetes. Finally,
we intended to evaluate the risk factors for lower limb
atherosclerotic plaque in the three diabetic groups.
Methods
Study population
This was a cross-sectional study and was partly based on
the data from our previous studies [10,24]. The diagnostic
criteria of newly diagnosed diabetes, diabetic ketosis,
ketosis-onset diabetes and non-ketotic type 2 diabetes have
been well-described in our previous study [10]. In addition,
type 1 diabetes was defined as diabetes with positive GAD
and/or IA-2 autoantibodies according to the standards of
the World Health Organization [1].
Among 497 Chinese patients (≥17 years old) with newly
diagnosed diabetes in our department between January
2007 and October 2008, 21 patients who did not meet
above criteria and were absent of complete data were
excluded (including two patients with positive islet-
associated autoantibodies but without performing
lower extremity ultrasonography). The other 476 pa-
tients were classified into three categories by above cri-
teria. That was, 53 were diagnosed for type 1 diabetes,
208 for ketosis-onset diabetes and 215 for non-ketotic
type 2 diabetes. Of these 53 patients with type 1 dia-
betes, 32 patients (60.4%) had isolated positive for GAD
autoantibodies, 9 patients (17.0%) isolated positive for IA-
2 autoantibodies, and 12 patients (22.6%) had combined
positive for GAD and IA-2 autoantibodies. In addition,
62 control participants with a fasting plasma glucose
(FPG) <6.0 mmol/L and a 2-h postprandial plasma glu-
cose (2-h PPG) <7.8 mmol/L during a 75 g oral glucose
tolerance test and with intact lower limb ultrasonography
measurements were age-matched to patients with ketosis-
onset diabetes.
The history of hypertension and cardio-cerebrovascular
events (CCEs), alcohol consumption and smoking habits
and medication use were obtained from all participants.
The definitions of smoking and alcohol use, hypertension
and CCEs were based on our previous studies [10,24,25].
The current uses of lipid-lowering drugs (LLDs), antihy-
pertensive drugs (AHDs) and aspirin were recorded yes or
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committee of Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital, and written consent was obtained
from all participants.
Physical and laboratory examinations
The physical and laboratory examinations used in this
study have been well-described in our previous studies
[10,24]. In brief, we have conducted a systematic phys-
ical and biochemical test from all diabetic patients.
Among these biochemical indicators, fasting and 2 hour
C-peptide were used to assess pancreatic islet function
of these patients, and the islet autoantibodies and ketosis
situation were available to the diagnostic typing of dia-
betes. In addition, weight was divided into underweight
(BMI < 18.5 kg/m2), overweight (23 to 24.9 kg/m2), and
obesity (BMI > 25 kg/m2) based on Asia-Pacific criteria
[26]. The glomerular filtration rate (GFR) was estimated
based on serum creatinine concentration using the sim-
plified MDRD formula: estimated GFR (eGFR) = 186.3 ×
(Serum creatinine)‐ 1.154 × (age)‐ 0.203 (×0.742 if female)
[27]. The 24 h urinary albumin excretion (UAE) was de-
termined as the mean of the values obtained from three
separate early morning urine samples in the period of
hospitalization. Urine ketones were collected from early
morning urine sample and measured by Legal’s test [10].
The autoantibodies against GAD and IA-2 were mea-
sured by ELISA (Euroimmun Medizinische Labordiag-
nostika AG, Germany).
Ultrasonography measurements
Color duplex ultrasonography was conducted by three
trained, certified sonographers using a Acuson Sequoia
512 scanner (Siemens Medical Solutions, Mountain
View, CA) with a 5–13 MHz linear transducer accord-
ing to our previous methods [24,28]. Briefly, the study
procedure involved scanning bilateral common femoral
artery, profunda femoris artery, superficial femoral ar-
tery, popliteal artery, anterior tibial artery, posterior
tibial artery, and peroneal artery for the presence of ath-
erosclerotic plaque and stenosis. The femoral intima-
media thickness (FIMT) on both sides was measured as
the distance between the leading edge of the lumen-
intima echo and the leading edge of the media-adventitia
echo. Mean FIMT was defined as the mean values of bi-
lateral FIMTs. Lower limb atherosclerotic plaque was
defined as the presence of a focal structure encroaching
into the arterial lumen of 0.5 mm or at least 50% greater
than the thickness of the surrounding vessel wall or
IMT of >1.5 mm in any of the above-mentioned lower
limb arteries segments based on the Mannheim consen-
sus [29]. Based on previous literatures [28,30-32], sig-
nificant lower limb arterial stenosis was defined as
luminal stenosis ≥ 50% and/or peak systolic velocity(PSV) ratio of ≥ 2.0 in at least one above-mentioned ar-
teries. The reproducibility of measurements of lower
limb atherosclerotic lesions has been reported in our
previous study [28].
Statistical analyses
The data were analyzed using SPSS 15.0 software. For
continuous variables, normality was checked. If the data
showed a normal distribution, variables were given as
the mean ± S.D., and one-way ANOVA with LSD was
used to determine differences among groups. If the data
were not distributed normally, the Kruskal-Wallis test was
employed and variables were expressed as median with
interquartile range. For categorical variables, they were
demonstrated by either absolute numbers or percentages.
Chi-squared statistical analysis was used to evaluate the
differences in categorical variables. Binary, multinomial
logistic and linear regressions were applied to assess dif-
ferences in categorical and continuous variables after
controlling for age and/or sex. Spearman correlation
was utilized to determine the intra-observer and inter-
observer reproducibility. Binary logistic regression was
performed to explore risk factors for lower limb athero-
sclerotic plaque. P < 0.05 (two-sided) was considered to
be statistically significant. P < 0.10 (two-sided) was con-
sidered to be evident of statistical trends.
Results
Characteristics of the study subjects
The clinical characteristics of the studied subjects are
manifested in Table 1. Both the type 1 and non-ketotic
type 2 diabetes showed an equal sex distribution, whereas
a strong male predominance was noted in the ketosis-
onset diabetes, even after adjusting for age. Smoking, alco-
hol use, prevalence of hypertension and CCEs, rate of use
of AHDs and aspirin, Body mass index (BMI), weight cat-
egory, diastolic blood pressure (DBP), triglyceride (TC),
high density lipoprotein cholesterol (HDL-C), FPG and
2 h PPG, fasting and 2 h C-peptide (FCP and 2 h PCP),
and hemoglobin A1C (HbA1C) also displayed significant
differences among the four groups after adjustment for
age and sex (all p < 0.05).
Comparison of lower limb atherosclerotic lesions
Figure 1 demonstrates the comparisons of lower limb
atherosclerotic lesions among the four groups after adjust-
ment for age and sex. The prevalence of lower limb ath-
erosclerotic plaque in the ketosis-onset diabetic group was
significantly higher than that in the control group (p =
0.013), and had a higher trend compared with the type 1
diabetic group (p = 0.072), but no significant difference
was observed in comparison to the non-ketotic type 2
diabetic group (p = 0.859), respectively (Figure 1A). The
odds ratio of lower limb atherosclerotic plaque in the






diabetes (n = 208)
Non-ketotic type 2
diabetes (n = 215)
p values *p values
Male (%) 43 (69.4%) 31 (58.5%) 153 (73.6%) 122 (56.7%) 0.002 0.030
Age (years) 47 ± 11 49 ± 18 49 ± 15 56 ± 14 <0.001 <0.001
Smoking (n, %) 38 (61.3%) 17 (32.1%) 84 (40.4%) 65 (30.2%) <0.001 0.001
Alcohol (n, %) 40 (64.5%) 14 (26.4%) 37 (17.8%) 36 (16.7%) <0.001 <0.001
Hypertension (%) 25 (40.3%) 11 (20.8%) 81 (38.9%) 98 (45.6%) 0.011 0.035
CCEs (%) 0 (0.0%) 2 (3.8%) 10 (4.8%) 31 (14.4%) 0.002 0.023
LLDs (%) 15 (24.2%) 10 (18.9%) 63 (30.3%) 70 (32.6%) 0.641 0.712
AHDs (%) 19 (30.6%) 8 (15.1%) 68 (32.7%) 95 (44.2%) 0.012 0.029
Aspirin (%) 8 (12.9%) 18 (34.0%) 66 (31.7%) 74 (34.4%) 0.009 0.013
BMI (kg/m2) 24.14 ± 3.67 22.34 ± 4.35 25.05 ± 3.54 25.16 ± 3.59 <0.001 <0.001
WHR 0.92 ± 0.07 0.89 ± 0.07 0.91 + 0.06 0.91 + 0.06 0.019 0.475
**Weight category <0.001 <0.001
Underweight 3 (4.4%) 8 (15.1%) 3 (1.4%) 2 (0.9%) —— ——
Overweight 20 (32.3%) 6 (11.3%) 48 (23.1%) 49 (22.8%) —— ——
Obesity 22 (35.5%) 11 (20.8%) 97 (46.6%) 109 (50.7%) —— ——
SBP (mmHg) 124 ± 16 125 ± 17 127 ± 15 130 ± 17 0.042 0.146
DBP (mmHg) 78 ± 12 79 ± 10 81 ± 11 81 ± 9 0.101 0.023
*TG (mmol/l) 1.18 (0.88-1.92) 1.21 (0.84-1.55) 1.44 (1.00-2.19) 1.49 (1.08-2.21) 0.001 0.019
TC (mmol/l) 4.84 ± 1.02 4.83 ± 1.09 5.03 ± 1.22 4.82 ± 1.22 0.323 0.695
HDL-C (mmol/l) 1.28 ± 0.35 1.13 ± 0.26 1.05 ± 0.27 1.11 ± 0.25 <0.001 <0.001
LDL-C (mmol/l) 2.71 ± 0.88 3.24 ± 0.97 3.40 ± 1.03 3.12 ± 0.97 <0.001 0.075
*Cr (μmol/l) 71 (56–82) 59 (48–79) 68 (58–80) 67 (54–79) 0.036 0.442
*UAE (mg/24 h) —— 9.9 (7.1-18.1) 10.3 (6.5-23.8) 8.9 (6.4-24.8) 0.823 0.917
*eGFR (ml/min/1.73 m2) 103 (93–116) 109 (89–136) 112 (92–134) 98 (82–118) 0.432 0.588
*FPG (mmol/l) 4.96 (4.67-5.24) 7.99 (6.02-11.44) 9.74 (7.63-12.45) 7.53 (6.39-9.67) <0.001 <0.001
*2 h PPG (mmol/l) 5.84 (5.04-6.58) 14.66 (10.49-19.61) 16.66 (12.94-20.79) 13.14 (10.39-16.66) <0.001 <0.001
*FCP (ng/mL) 2.05 (1.6-3.03) 0.6 (0.3-0.84) 1.23 (0.74-1.92) 2.02 (1.36-2.93) <0.001 0.030
*2 h C-P (ng/mL) 7.99 (6.56-9.92) 0.92 (0.62-1.77) 2.31 (1.55-3.66) 4.65 (3.12-6.35) <0.001 0.004
HA1C (%) 5.3 ± 0.34 12.39 ± 2.36 11.83 ± 2.05 9.81 ± 2.58 <0.001 <0.001
Values are presented as mean ± SD, median with interquartile range, or percentages. *Non-normal distribution of continuous variables. **Weight was divided into
underweight (BMI < 18.5 kg/m2), overweight (23 to 24.9 kg/m2), and obesity (BMI > 25 kg/m2) based on Asia-Pacific criteria.
P value: The p-values were not adjusted for age and sex for the trend.
*P value: The *p value were adjusted by age and sex for the trend.
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groups, using the control group as a reference [OR, 3.48
(95% CI, 1.38-8.77) for the ketosis-onset diabetes; OR,
1.62 (95% CI, 0.38-6.91) for the type 1 diabetes; OR,
3.16 (95% CI, 1.10-9.09) for the non-ketotic type 2 dia-
betes]. The odds ratio of lower limb atherosclerotic
plaque exhibited difference between the ketosis-onset
and type 1 diabetes (p = 0.062), but no difference be-
tween the ketosis-onset and non-ketotic type 2 diabetic
patients (p = 0.613) (Figure 1B).
Contrary to lower limb atherosclerotic plaque, there
was no statistical significance in the prevalence of lowerlimb stenosis among the control group (4.8%), the type
1 diabetic group (0%), the ketosis-onset diabetic group
(2.9%) and non-ketotic type 2 diabetic group (7.4%) after
controlling for age and sex (p = 0.167) (Figure 1C).
Similar to lower limb atherosclerotic plaque, the mean
FIMT in the ketosis-onset diabetes (0.73 ± 0.17 mm)
was markedly higher than that in the control subjects
(0.69 ± 0.13 mm, p = 0.045), but no significant differences
were found among the ketosis-onset diabetes, type 1 dia-
betes (0.71 ± 0.16 mm, p = 0.373), and non-ketotic type 2
diabetes (0.80 ± 0.22 mm, p = 0.280) after controlling for
age and sex (Figure 1D).
Figure 1 Comparison of lower limb atherosclerotic lesions among the four groups after adjusting for age and sex. (A) Comparison of
the prevalence of lower limb atherosclerotic plaque among the four groups. The p-value for four group comparisons was 0.013. (B) Odd ratio of
lower limb atherosclerotic plaque for the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects in comparison to control subjects without
diabetes. The bars represent the 95% confidence interval. Compared with control subjects, where *p = 0.002 and **p = 0.041. (C) Comparison of
the prevalence of lower limb stenosis among the four groups. The p-value for four group comparisons was 0.167. (D) Comparison of the mean
FIMT among the four groups. The p-value for four group comparisons was 0.015.
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stratified by sex and age in each diabetic group
Analyses of lower limb atherosclerotic lesions stratified
by sex and age in each diabetic group are showed in
Figure 2. A significant sex-related difference and a remark-
able increase with age were found in the prevalence of
lower limb atherosclerotic plaque in each diabetic group
(Figure 2A, B). Interestingly, the prevalence of lower limb
atherosclerotic plaque in the ketosis-onset diabetes was
higher in female than in male after adjustment for age, op-
posite to the type 1 and non-ketotic type 2 diabetes. The
prevalence of lower limb stenosis also demonstrated sig-
nificant sex- and age-related differences in the ketosis-
onset and non-ketotic type 2 diabetic groups, rather
than in the type 1 diabetic group (Figure 2C, D). The
mean FIMT remarkably increased with age, but had no
statistical significance between sexes in each subgroup
(Figure 2E and F).Comparison of the mean FIMT between the subjects with
and without lower limb plaque in each diabetic group
Figure 3 compares the mean FIMT value of the subjects
with and without lower limb atherosclerotic plaque after
controlling for age and sex in each diabetic group. In both
the ketosis-onset (0.64 ± 0.10 mm and 0.85 ± 0.17 mm for
the subjects without and with lower limb atherosclerotic
plaque, respectively, p < 0.001) and non-ketotic (0.71 ±
0.16 mm and 0.87 ± 0.24 mm for the subjects without and
with lower limb atherosclerotic plaque, respectively, p =
0.049) diabetic groups, the mean FIMT value was mark-
edly higher in the subjects with lower limb atherosclerotic
plaque than those without lower limb atherosclerotic
plaque. In contrast, there was no significant difference in
the mean FIMT value between the type 1 diabetic patients
without and with lower limb atherosclerotic plaque after
controlling for age and sex (0.66 ± 0.18 mm and 0.78 ±
0.11 mm, respectively, p = 0.443).
Figure 2 Comparison of lower limb atherosclerotic lesions stratified by sex and age in diabetics. (A) The prevalence of lower limb
atherosclerotic plaque stratified by sex in the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects after adjusting for age. (B) The prevalence
of lower limb atherosclerotic plaque stratified by age in the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects after adjusting for sex.
The p-values for group comparisons were successively 0.001, <0.001 and <0.001 in the type 1 diabetic subjects, ketosis-onset and non-ketotic type 2
diabetic subjects. (C) The prevalence of lower limb stenosis stratified by sex in the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects after
adjusting for age. (D) The prevalence of lower limb stenosis stratified by age in the type 1, ketosis-onset and non-ketotic type 2 diabetic
subjects for sex. The p-values for group comparisons were 0.001 and <0.001 in the ketosis-onset and non-ketotic type 2 diabetic subjects,
respectively. (E) Comparison of mean FIMT stratified by sex in the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects after adjusting
for age. (F) Comparison of mean FIMT stratified by age in the type 1, ketosis-onset and non-ketotic type 2 diabetic subjects after adjusting for
sex. The p-values for group comparisons were all <0.001 in type 1 diabetic subjects and ketosis-onset and non-ketotic type 2 diabetic subjects.
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plaque in diabetic patients
The risk factors for lower limb atherosclerotic plaque were
performed by binary logistic regression analyses after
adjusting for the variables in Table 1. In the type 1 diabetes,
sex (women) [Exp (B), 17.03 (95% CI, 1.28-26.88), p = 0.03]
and age [Exp (B), 1.35 (95% CI, 1.07-1.69), p = 0.01] were
significantly associated with lower limb atherosclerotic
plaque. In the non-ketotic type 2 diabetes, age [Exp (B),
1.12 (95% CI, 1.07-1.18), p < 0.001] and mean FIMT
[Exp (B), 1.01 (95% CI, 1.00-1.01), p = 0.013] wereindependent risk factors for lower limb atherosclerotic
plaque. Interestingly, the ketosis-onset diabetic patients
had the same risk factors for lower limb atherosclerotic
plaque [Exp (B), 1.20 (95% CI, 1.11-1.30) for age, p <
0.001; Exp (B), 1.04 (95% CI, 1.02-1.06) for mean FIMT,
p < 0.001] as the non-ketotic type 2 diabetes. For all dia-
betic patients, sex (women) [Exp (B), 2.13 (95% CI, 1.12-
4.08), p = 0.022], age [Exp (B), 1.15 (95% CI, 1.11-1.20),
p < 0.001] and mean FIMT [Exp (B), 1.01 (95% CI,
1.005-1.014), p < 0.001] were risk factors for lower limb
atherosclerotic plaque.
Figure 3 Comparison of the mean FIMT in subjects with and without lower limb atherosclerotic plaque in each diabetic group.
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The present study showed that the atherosclerotic charac-
teristics of the ketosis-onset diabetes were similar to those
of the non-ketotic type 2 diabetes rather than the type 1
diabetes, which provided powerful clinical evidences for
the classification of ketosis-onset diabetes from the point
of macrovascular lesions.
The immunology and pathophysiology of ketosis-onset
diabetes have been sufficiently studied by other investiga-
tors [7,8]. However, data were limited regarding macrovas-
cular complications in ketosis-onset diabetes. Although we
previously have compared features of carotid atheroscler-
osis between ketosis-onset diabetes and non-ketotic type 2
diabetes [10], it is not entirely clear whether similar athero-
sclerotic features exhibited between ketosis-onset and type
1 diabetes, due to a lack of type 1 diabetic group in our
previous study. Therefore, we carried out the present study
to comprehensively compare atherosclerotic characteristics
among type 1, ketosis-onset and non-ketotic type 2 dia-
betes and to further investigate whether similar athero-
sclerotic changes between ketosis-onset diabetes and
non-ketotic type 2 diabetes are a common phenomenon
in other arteries, not just in carotid arteries. To the best
of our knowledge, this is the first time to systematically
compare atherosclerotic lesions among type 1, ketosis-
onset, and non-ketotic type 2 diabetes.
Consistent with previous reports [7,8,33], our results
showed the proportion of overweight or obesity as well
as BMI value were almost identical in the ketosis-onset
and non-ketotic type 2 diabetes, but were remarkably
higher compared with the type 1 diabetes. The levels of
FCP and 2 h PCP in the patients with ketosis-onset dia-
betes was intermediate between those with type 1 and
type 2 diabetes, partly explained by the fact that ketosis-
onset diabetes has a predominant insulin secretory defect
rather than a decline in beta-cell mass months after recov-
ery from the index episode of ketoacidosis [4,34,35]. FPG
and 2 h PPG in the ketosis-onset diabetes were higher
than in the type 1 and non-ketotic type 2 diabetes, whichsuggested that the impairment of beta-cell was acute in
ketosis-onset diabetes [36]. The exact mechanisms of tran-
sient beta-cell failure in ketosis-onset diabetes have not
been clarified yet, but several lines of evidence indicated a
genetic propensity to glucotoxicity- or glucolipotoxicity-
induced oxidative stress might be responsible for transient
beta-cell function [37,38]. For example, Sobngwi et al. [39]
found ketosis-prone type 2 diabetes was associated with
low glucose-6-phosphate dehydrogenase activity, an intra-
cellular enzyme essential to defense mechanisms against
oxidative stress.
In addition, our study found that the prevalence of
ketosis-onset diabetes is approximately 50% in Chinese pa-
tients with newly diagnosed diabetes, though the incidence
of that is unknown for now. The possible reason that nearly
half of newly diagnosed diabetic subjects had ketosis-onset
is that the illness of patients with ketosis-onset diabetes
tended to be more serious; thus patients with ketosis-onset
diabetes are more likely to be hospitalized.
In keep with features of carotid plaque of ketosis-
onset diabetes in our previous study [10], the prevalence
of lower limb atherosclerotic plaque in the ketosis-onset
diabetic patients was also remarkably higher relative to
the subjects without diabetes and also significantly in-
creased with age. In accordance with our results, Danese
et al. [40] demonstrated that diabetes was significantly
associated with the presence of atherosclerotic plaques
in lower limb district in a retrospective study. Rajala
et al. [41] revealed that the prevalence of atheromatous
plaques in femoral arteries was 77% in elderly Finns with
diabetes mellitus or impaired glucose tolerance, close to
our previous study [24], which clarified that elderly pa-
tients had a higher prevalence of lower limb atheroscler-
osis than younger patients in Chinese type 2 diabetes.
Moreover, taking the subjects without diabetes as a ref-
erence, the 3.48-fold risk of lower limb atherosclerotic
plaque in the ketosis-onset diabetes came near the non-
ketotic type 2 diabetes, but higher than the type 1 dia-
betes, possibly due to later-onset age, higher BMI, and
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ketosis-onset diabetes versus type 1 diabetes. For the
ketosis-onset diabetes, the prevalence and risk of lower
limb atherosclerotic plaque were higher than that of ca-
rotid atherosclerotic plaque we previously reported [10],
explained by the fact that atherosclerotic lesions were
more frequent in femoral arteries than carotid arteries
independent of increasing number of risk factors [42,43].
Unlike no sex difference in the prevalence of carotid
atherosclerotic plaque [10], female with ketosis-onset
diabetes had a much higher prevalence of lower limb
atherosclerotic plaque than male. Amusingly, contrary to
gender feature of lower limb atherosclerotic plaque in
the ketosis-onset diabetes, the type 1 and non-ketotic
type 2 diabetes in the present study had higher lower
limb atherosclerotic plaque in male than in female as
shown by previous studies [24,44]. The reason for this
sex-discrepancy between the ketosis-onset diabetes and
type 1 and type 2 diabetes may attribute to strong male
predomination in the ketosis-onset diabetes compared
with an equal ratio of sex in the type 1 and type 2 diabetes,
which suggested that the ketosis-onset diabetes possessed
its own characteristics in lower limb atherosclerotic le-
sions, even though most of lower limb atherosclerotic fea-
tures in the ketosis-onset diabetes were approximately
same as the non-ketotic type 2 diabetes. Considered de-
tection of lower limb atherosclerotic plaque by ultrasound
as a subclinical indicator of cardiovascular events [45-47],
early detection and adequate treatment of atherosclerosis
are beneficial to the prevention of future cardiovascular
events in ketosis-onset diabetes.
Similar to the prevalence of carotid stenosis of ketosis-
onset diabetes in our previous study [10], no obvious dif-
ference was observed in the prevalence of lower limb
stenosis among the four groups. Consistent with our
findings, two previous studies [48,49] reported that no
significant differences were found between the patients
with and without diabetes in the percentage of stenosis
of below-knee arteries. The reason for this may be that
stenosis was the late-stage vascular dysfunction of dia-
betes, whereas our study subjects were newly diagnosed
diabetes, so the prevalence of stenosis in our study was
relatively low, contributing to no different prevalence of
stenosis among different groups. Different from the preva-
lence of carotid stenosis without sex and age differences
in ketosis-onset diabetes [10], the prevalence of lower limb
stenosis was remarkably higher in men than in women
and increased with age in both the ketosis-onset and non-
ketotic type 2 diabetes, but not in the type 1 diabetes.
American Diabetes Association stated that the risk of per-
ipheral arterial disease increases by age in diabetic patients
[50]. For example, Tseng [51] demonstrated that older age
was an independent risk factor for peripheral arterial
obstructive disease in Taiwanese patients with type 2diabetes. The sex- and age-related differences of lower
limb stenosis between the type 1 diabetes and ketosis-
onset and type 2 diabetes may be that the numbers of
subjects were relatively small (53 patients) and there were
no patients with lower limb stenosis in the type 1 diabetic
group. Given that lower limb stenosis is associated with
the extent and prognosis of coronary artery disease [52],
the appearance of lower limb stenosis can be served as a
prognostic indictor of coronary artery disease in ketosis-
onset diabetes.
The mean CIMT of ketosis-onset diabetes in our pre-
vious study [10] was significantly higher than control
subjects and remarkably related to age, but not sex. Add-
itionally, the patients with carotid plaque had remarkably
a higher mean CIMT than those without carotid plaque
for ketosis-onset diabetes. The mean FIMT of the ketosis-
onset diabetes in our current study had the same features
as the mean CIMT in our previous study. Consistent with
our results, Kogawa et al. [53] reported that the mean
FIMT of subjects with type 2 diabetes mellitus was re-
markably higher than those without diabetes. Kirhmajer
et al. [54] reported that FIMT in patients with coronary
artery disease was increased compared with those with-
out coronary artery disease, and triglycerides, BMI, male
gender and smoking was an independent risk factor for in-
creased FIMT. No sex-related differences in the FIMT of
ketosis-onset diabetes can be explained by the Bogalusa
heart study [55], which found that age-adjusted FIMT
showed gender differences only among young adult whites
rather than blacks and suggested that ethnic differences
might be major contributors to no sex-related differences
in the FIMT. Seeing that increased FIMT can predict
extent and severity of coronary artery disease [56,57], the
usefulness of FIMT can be used for assessing the out-
comes of coronary artery disease in ketosis-onset diabetes.
The mean FIMT existed significant difference between
the patient without and with lower limb plaque in the
ketosis-onset and non-ketotic type 2 diabetic subjects,
rather than in the type 1 diabetic subjects. We cannot
successfully explain this finding. A possible explanation
for this observation may be that ketosis-onset diabetes
and type 2 diabetes shared the similar pathogenesis of
atherosclerosis.
In keep with risk factors of carotid plaque of the ketosis-
onset diabetes in our previous study [10], age and mean
FIMT were independent risk factors for the presence of
lower limb plaque in the ketosis-onset diabetes. More
interestingly, risk factors of lower limb plaque in the
ketosis-onset diabetes were the same as those in the non-
ketotic type 2 diabetes, but not the type 1 diabetes, which
indirectly supported the idea for classifying ketosis-onset
diabetes as a subtype of type 2 diabetes.
Our study has important clinical implications. First, the
general clinical features and macrovascular complications
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betes rather than type 1 diabetes, whereas there were also
some similar features between ketosis-onset diabetes and
type 1 diabetes. Therefore, our study provided powerful
evidences for the hypothesis that diabetes is a heteroge-
neous disease [58]. Secondly, there was a higher preva-
lence of atherosclerotic plaque in ketosis-onset diabetes
than normal controls, so early screening and intervention
were beneficial to reduce future cardiovascular events. Fi-
nally, due to ketosis-onset diabetes more inclined to type
2 diabetes, the clinical treatments of ketosis-onset diabetes
should be similar to those of type 2, but not type 1 dia-
betes. For example, the individuals with ketosis-onset dia-
betes are able to maintain optimal glycemic control on
oral antidiabetic agents after recovering from the initial
crisis with insulin therapy [8].
There are several limitations to our study. First, the
cross-sectional design restricted our ability to assess the
evolutionary process of atherosclerotic lesions. Further
prospective studies are needed to clarify the characteris-
tics of atherosclerotic development in ketosis-prone dia-
betes. Secondly, the age of the type 1 diabetic subjects in
our study was older than usual. However, because ath-
erosclerosis is closely related to age, our study excluded
the patients with diabetes aged less than 17 years old.
The patients with type 1 diabetes in our study included
both classical type 1 diabetes at early-onset age and la-
tent autoimmune diabetes in adults (LADA), a subtype
of type 1 diabetes at late-onset age, therefore, the patients
with type 1 diabetes in our study was more comparable to
those with type 2 diabetes. Otherwise, if merely including
classical type 1 diabetes, it can lead to the wrong conclu-
sions. Thirdly, ketosis-onset diabetes in our study may not
be fully equal to ketosis-prone diabetes, as data like PH
and anion gap are not available in the present study, which
identify whether patients have ketoacidosis or not. Finally,
this was merely a single-center study with a relatively
small number of patients, thus the multi-center studies in
a larger sample should be performed to further clarify the
atherosclerotic features of ketosis-prone diabetes.Conclusions
In conclusion, the prevalence and risk of lower limb ath-
erosclerotic lesions in the ketosis-onset diabetes were re-
markably higher than those of the control subjects
without diabetes. The manifestations and risk factors of
lower limb atherosclerotic plaque in the ketosis-onset
diabetes were more similar to those in the non-ketotic
type 2 diabetes rather than the type 1 diabetes. Therefore,
the current study provided further clinical evidences to
support the classification of ketosis-onset diabetes as a
subtype of type 2 diabetes rather than idiopathic type 1
diabetes in adults.Abbreviations
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